药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2015年
3期
309-312
,共4页
顾中盛%吴昊%房文通%李茜
顧中盛%吳昊%房文通%李茜
고중성%오호%방문통%리천
呕吐%顺铂%奥氮平%托烷司琼%地塞米松
嘔吐%順鉑%奧氮平%託烷司瓊%地塞米鬆
구토%순박%오담평%탁완사경%지새미송
Vomiting%Cisplatin%Olanzapine%Tropisetron%Dexamethasone
目的：观察奥氮平联合托烷司琼、地塞米松预防顺铂所致恶心、呕吐的疗效及不良反应。方法：符合入选标准的肺癌患者，均采用含顺铂的化疗方案，随机分为奥氮平组和对照组，观察两种止吐方案防治顺铂所致恶心、呕吐的疗效及不良反应。结果：奥氮平组和对照组分别纳入42例和40例患者，两组间一般临床资料无统计学差异（P>0.05）。奥氮平组和对照组恶心、呕吐症状评分分别为9.44±3.61、12.25±3.66（P=0.012），用药后的恶心、呕吐分级（P=0.046）和止吐效果（P=0.043）有统计学差异，特别是呕吐完全控制率显著提高（54.76% vs 25.00%，P=0.006）。亚组分析发现，奥氮平组女性患者的有效率较高，年龄、KPS、肿瘤分期对有效率无影响。治疗期间两组患者均出现头晕、乏力、便秘和血糖升高，无统计学差异。结论：奥氮平联合止吐方案防治顺铂所致恶心、呕吐具有较好的临床效果，不良反应少，值得推广。
目的：觀察奧氮平聯閤託烷司瓊、地塞米鬆預防順鉑所緻噁心、嘔吐的療效及不良反應。方法：符閤入選標準的肺癌患者，均採用含順鉑的化療方案，隨機分為奧氮平組和對照組，觀察兩種止吐方案防治順鉑所緻噁心、嘔吐的療效及不良反應。結果：奧氮平組和對照組分彆納入42例和40例患者，兩組間一般臨床資料無統計學差異（P>0.05）。奧氮平組和對照組噁心、嘔吐癥狀評分分彆為9.44±3.61、12.25±3.66（P=0.012），用藥後的噁心、嘔吐分級（P=0.046）和止吐效果（P=0.043）有統計學差異，特彆是嘔吐完全控製率顯著提高（54.76% vs 25.00%，P=0.006）。亞組分析髮現，奧氮平組女性患者的有效率較高，年齡、KPS、腫瘤分期對有效率無影響。治療期間兩組患者均齣現頭暈、乏力、便祕和血糖升高，無統計學差異。結論：奧氮平聯閤止吐方案防治順鉑所緻噁心、嘔吐具有較好的臨床效果，不良反應少，值得推廣。
목적：관찰오담평연합탁완사경、지새미송예방순박소치악심、구토적료효급불량반응。방법：부합입선표준적폐암환자，균채용함순박적화료방안，수궤분위오담평조화대조조，관찰량충지토방안방치순박소치악심、구토적료효급불량반응。결과：오담평조화대조조분별납입42례화40례환자，량조간일반림상자료무통계학차이（P>0.05）。오담평조화대조조악심、구토증상평분분별위9.44±3.61、12.25±3.66（P=0.012），용약후적악심、구토분급（P=0.046）화지토효과（P=0.043）유통계학차이，특별시구토완전공제솔현저제고（54.76% vs 25.00%，P=0.006）。아조분석발현，오담평조녀성환자적유효솔교고，년령、KPS、종류분기대유효솔무영향。치료기간량조환자균출현두훈、핍력、편비화혈당승고，무통계학차이。결론：오담평연합지토방안방치순박소치악심、구토구유교호적림상효과，불량반응소，치득추엄。
O bjective: To observe the efficacy and adverse reactions of olanzapine joint tropisetron and dexamethasone in prevention of nausea and vomiting induced by cisplatin. Methods: Lung cancer patients who used cisplatin-containing chemotherapy and met the inclusion criteria were randomly divided into olanza-pine group and control group. The efficacy and adverse reactions of the two groups were recorded. Results:Forty-two patients were included in the olanzapine group, and forty patients were included in the control group. Common clinical data of the two groups had no significant difference (P>0.05). Nausea and vomiting scores of the olanzapine group and the control group were 9.44±3.61 and 12.25±3.66 (P=0.012). There were significant difference in nausea and vomiting grading (P=0.046) and controlling (P=0.043), particularly in the full control rates of nausea and vomiting (54.76% vs 25.00%, P=0.006). Subgroup analysis found that olanzap-ine was more efficient in female patients, however, age, KPS and tumor stage had no effect on efficiency. Pa-tients in both groups occurred dizziness, fatigue, constipation and elevated blood sugar (P>0.05). Conclusion:Olanzapine can improve cisplatin-induced nausea and vomiting with well-tolerated adverse reactions.
